FOR RESEARCHERS
Open RUNX1 Research Grants
RRP and Alex's Lemonade Stand Foundation (ALSF)
Early Career Investigator (ECI) Grant Program
The RRP-ALSF ECI Grant Program, an ongoing partnership between RRP and Alex’s Lemonade Stand Foundation, supports early-career scientists focused on inherited hematologic malignancy predisposition disorders, particularly RUNX1-FPD. This program provides funding to advance innovative research aimed at preventing the progression of pre-malignancy to hematologic malignancy in RUNX1-FPD patients.
Program Highlights
Focus Areas
Research proposals must be relevant to the goal of preventing the evolution to hematologic malignancies in RUNX1-FPD. Proposals that seek to translate from bench to bedside will receive priority.
Eligibility
U.S. and international applicants are welcome.
Funds must be granted to non-profit institutions or organizations.
Must hold an MD, PhD or MD/PhD (or equivalent) and be within five years of a first faculty appointment as Assistant Professor or equivalent.
75% of the applicant’s time must be dedicated to research activities.
Grant Terms & Budget
Up to $60,000 per year for 3 years, totaling $180,000. No indirect costs are covered.
Data sharing is a priority for this research program and an expected outcome of a completed project.
Grant recipients will be expected to present progress annually at a scientific meeting hosted by RRP.
Key Dates
Application Deadline: December 19, 2024
Award Notification: March 2025
Project Start Date: April 2025
RRP Cancer Interception/ Prevention Research Roadmap
Our roadmap is simple. We only invest in research that brings us one step closer to our end goal. We understand that discovering medicines requires the right tools (i.e. disease models and laboratory reagents) and the right datasets (i.e. patient clinical and genomic data, as well as patient biospecimens). We have defined 4 rational therapeutic approaches to preventing blood cancer:
1) selectively targeting precancerous cells;
2) increasing RUNX1 activity;
3) decreasing cancer-causing inflammation;
4) fixing or replacing RUNX1-mutated cells using cell or gene therapy.
